Modality
Small Molecule
MOA
Anti-Aβ
Target
GIP-R
Pathway
Epigenetic
SMAMCC
Development Pipeline
Preclinical
~Sep 2016
→ ~Dec 2017
Phase 1
Mar 2018
→ Jan 2031
Phase 1Current
NCT06316248
683 pts·SMA
2018-03→2031-01·Active
NCT06918789
1,726 pts·SMA
2021-09→2027-09·Terminated
2,409 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-09-091.4y awayInterim· SMA
2031-01-064.8y awayInterim· SMA
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1
Active
P1
Termina…
Catalysts
Interim
2027-09-09 · 1.4y away
SMA
Interim
2031-01-06 · 4.8y away
SMA
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06316248 | Phase 1 | SMA | Active | 683 | HAM-D |
| NCT06918789 | Phase 1 | SMA | Terminated | 1726 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R |